ARTA
ALPN

A.R.T. Advisors’s Alpine Immune Sciences Inc ALPN Stock Holding History

A.R.T. Advisors’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,411
Closed -$81K – 1737
2017
Q2 		$81K Sell
8,411
-7,008
-45% -$67.2K ﹤0.01% 1272
2017
Q1 		$180K Buy
+15,419
New +$156K 0.01% 1184

Other funds holding ALPN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

A.R.T. Advisors's ALPN Position: Q3 2017 in Review

A.R.T. Advisors sold out of Alpine Immune Sciences Inc (ALPN) in Q3 2017, closing a stake of 8,411 shares — an estimated $81K sold.

A.R.T. Advisors first reported a position in ALPN in Q1 2017 and held it in 2 quarters. The position peaked at $180K in Q1 2017. 24 funds tracked by Wall St. Rank hold ALPN as of Q3 2017.

  • A.R.T. Advisors reported no remaining Alpine Immune Sciences Inc position as of Q3 2017 after selling out during the quarter.
  • A.R.T. Advisors sold 8,411 Alpine Immune Sciences Inc shares in Q3 2017, an estimated $81K.
  • A.R.T. Advisors first reported a position in Alpine Immune Sciences Inc in Q1 2017 and held it in 2 quarters.
  • A.R.T. Advisors's Alpine Immune Sciences Inc position peaked at $180K in Q1 2017.
  • 24 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q3 2017.

Based on A.R.T. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.